HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.
EPN 2018

Antonio Ruggiero

Antonio Ruggiero, Speaker at Neonatal conferences
Catholic University, Italy
Title : Risk factors and management of anthracyclines-related cardiotoxicity in childhood cancers


Anthracyclines are among the most effective antineoplastic drugs and have gained widespread use in the treatment of numerous solid tumors and hematological malignancies. They can cause cytotoxic damage to cardiac cells, especially in combination with radiotherapy. Furthermore, cardiotoxicity increases with the cumulative dose and may lead to congestive heart failure and cardiomyopathy. Other factors, including age, pre-existing cardiac disease, length of follow-up, gender, route of administration, concomitant exposure to some chemotherapeutic drugs, trisomy 21 and black race, play a role in increasing the risk of cardiac dysfunction. The protocol for the assessment of cardiac function in these patients should be based on a multi-modality approach. The prevention of anthracycline-induced cardiotoxicity is mandatory as children are expected to survive for decades after being cured of their cancer. Clinicians should investigate the presence of risk factors before starting therapy. Indeed, prompt recognition of modifiable risk factors can help reduce the cardiac damage and the development of acute heart failure.


Antonio Ruggiero received his medical degree from the Catholic University in Rome in 1992. He holds Board of Pediatrics in 1996 and Board of Pediatric Haematology and Oncology in 1998 at the Catholic University of Rome. Prof. Ruggiero is currently an associate professor in the Department of Pediatrics at the Catholic University of Rome where he is responsible for teaching Pediatrics and Pediatric Hematology and Oncology. His research interests focus on pediatric clinical trials, clinical pharmacology of antineoplastic drugs, pain therapy and pediatric drugs.